Riociguat (Riociguat)
Overview of Riociguat
Riociguat is methyl 4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo [3,4-b]pyridin-3-yl]-5-pyrimidinyl(methyl carbamate. It is a soluble guanylate cyclase (sGC) stimulator indicated for the treatment of adults with Persistent/recurrent Chronic Thromboembolic Pulmonary Hypertension (CTEPH) (WHO Group 4) after surgical treatment or inoperable CTEPH to improve exercise capacity and WHO functional class.It is also indicated for Pulmonary Arterial Hypertension (PAH) (WHO Group 1) to improve exercise capacity, improve WHO functional class and to delay clinical worsening.
Indication of Riociguat
Riociguat is primarily indicated in conditions like Chronic thromboembolic pulmonary hypertension, Pulmonary hypertension.
Contraindication of Riociguat
No data regarding the contra indications of Riociguat is available.
Side Effects of Riociguat
The symptomatic adverse reactions produced by Riociguat are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Headache, Nausea, Vomiting, Diarrhea, Constipation, Gastritis, Dyspepsia, Hypotension, Anemia, dizziness, dyspepsia, Hypotension, GI reflux.
Precautions of Riociguat
Symptomatic hypotension , Bleeding , Pulmonary edema in patients with pulmonary veno-occlusive disease. If confirmed, discontinue treatment.